FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298088251> ?p ?o ?g. }

• W4298088251 endingPage "2790" @default.
• W4298088251 startingPage "2782" @default.
• W4298088251 abstract "Combined treatment with tyrosine kinase inhibitors (TKI) plus anti-PD-1 antibodies showed high anti-tumor efficacy and made conversion resection possible for patients with unresectable hepatocellular carcinoma (HCC). However, long-term survival has not been reported.A cohort of consecutive patients who received combined TKI/anti-PD-1 antibodies as first-line treatment for initially unresectable HCC at the authors' hospital between August 2018 and September 2020 was eligible for this study. Patients who were responding to systemic therapy and met the criteria for hepatectomy underwent liver resection with curative intention. The study also investigated the association of clinical factors with successful conversion resection and postoperative recurrence.The study enrolled 101 patients including 24 patients (23.8 %) who underwent R0 resection a median of 3.9 months (interquartile range: 2.5-5.9 months) after initiation of systemic therapy. Patients with an Eastern cooperative oncology group performance status of 0, fewer intrahepatic tumors, or a radiographic response to systemic therapy were more likely to be able to receive curative resection. After a median follow-up period of 21.5 months, hepatectomy was independently associated with a favorable overall survival (hazard ratio [HR], 0.050; 95 % confidence interval [CI], 0.007-0.365; P = 0.003). For the 24 patients who underwent surgery, the 12-month recurrence-free survival and overall survival rates were respectively 75% and 95.8%. Achieving a pathologic complete response (n = 10) to systemic therapy was associated with a favorable recurrence-free survival after resection, with a trend toward significance (HR, 0.345; 95% CI, 0.067-1.785; P = 0.187).Selected patients with initially unresectable HCC can undergo hepatectomy after systemic therapy with combined TKI/anti-PD-1 antibodies. In this study, conversion resection was associated with a favorable prognosis." @default.
• W4298088251 created "2022-10-01" @default.
• W4298088251 creator A5002708668 @default.
• W4298088251 creator A5004612307 @default.
• W4298088251 creator A5017352295 @default.
• W4298088251 creator A5018323072 @default.
• W4298088251 creator A5029634246 @default.
• W4298088251 creator A5031371726 @default.
• W4298088251 creator A5038545320 @default.
• W4298088251 creator A5040984708 @default.
• W4298088251 creator A5042464922 @default.
• W4298088251 creator A5047500803 @default.
• W4298088251 creator A5056474525 @default.
• W4298088251 creator A5074151795 @default.
• W4298088251 creator A5079547381 @default.
• W4298088251 creator A5082725095 @default.
• W4298088251 creator A5089515440 @default.
• W4298088251 date "2022-09-30" @default.
• W4298088251 modified "2023-10-18" @default.
• W4298088251 title "Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma" @default.
• W4298088251 cites W1971837077 @default.
• W4298088251 cites W2028319026 @default.
• W4298088251 cites W2787358630 @default.
• W4298088251 cites W2890595557 @default.
• W4298088251 cites W2981868918 @default.
• W4298088251 cites W3008514541 @default.
• W4298088251 cites W3025022288 @default.
• W4298088251 cites W3045387409 @default.
• W4298088251 cites W3093964219 @default.
• W4298088251 cites W3099108820 @default.
• W4298088251 cites W3121026211 @default.
• W4298088251 cites W3137254944 @default.
• W4298088251 cites W3138484572 @default.
• W4298088251 cites W3149900842 @default.
• W4298088251 cites W3158785061 @default.
• W4298088251 cites W3166753505 @default.
• W4298088251 cites W3167434284 @default.
• W4298088251 cites W3169064984 @default.
• W4298088251 cites W3186127018 @default.
• W4298088251 cites W3186601765 @default.
• W4298088251 cites W3205073738 @default.
• W4298088251 cites W3208308450 @default.
• W4298088251 cites W3211846837 @default.
• W4298088251 cites W3213277274 @default.
• W4298088251 cites W3214415684 @default.
• W4298088251 cites W4200201228 @default.
• W4298088251 cites W4200388794 @default.
• W4298088251 cites W4225263869 @default.
• W4298088251 cites W4286294458 @default.
• W4298088251 doi "https://doi.org/10.1245/s10434-022-12530-z" @default.
• W4298088251 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36178565" @default.
• W4298088251 hasPublicationYear "2022" @default.
• W4298088251 type Work @default.
• W4298088251 citedByCount "10" @default.
• W4298088251 countsByYear W42980882512022 @default.
• W4298088251 countsByYear W42980882512023 @default.
• W4298088251 crossrefType "journal-article" @default.
• W4298088251 hasAuthorship W4298088251A5002708668 @default.
• W4298088251 hasAuthorship W4298088251A5004612307 @default.
• W4298088251 hasAuthorship W4298088251A5017352295 @default.
• W4298088251 hasAuthorship W4298088251A5018323072 @default.
• W4298088251 hasAuthorship W4298088251A5029634246 @default.
• W4298088251 hasAuthorship W4298088251A5031371726 @default.
• W4298088251 hasAuthorship W4298088251A5038545320 @default.
• W4298088251 hasAuthorship W4298088251A5040984708 @default.
• W4298088251 hasAuthorship W4298088251A5042464922 @default.
• W4298088251 hasAuthorship W4298088251A5047500803 @default.
• W4298088251 hasAuthorship W4298088251A5056474525 @default.
• W4298088251 hasAuthorship W4298088251A5074151795 @default.
• W4298088251 hasAuthorship W4298088251A5079547381 @default.
• W4298088251 hasAuthorship W4298088251A5082725095 @default.
• W4298088251 hasAuthorship W4298088251A5089515440 @default.
• W4298088251 hasBestOaLocation W42980882511 @default.
• W4298088251 hasConcept C119060515 @default.
• W4298088251 hasConcept C126322002 @default.
• W4298088251 hasConcept C141071460 @default.
• W4298088251 hasConcept C143998085 @default.
• W4298088251 hasConcept C159110652 @default.
• W4298088251 hasConcept C207103383 @default.
• W4298088251 hasConcept C2776909242 @default.
• W4298088251 hasConcept C2778019345 @default.
• W4298088251 hasConcept C2780140570 @default.
• W4298088251 hasConcept C44249647 @default.
• W4298088251 hasConcept C71924100 @default.
• W4298088251 hasConcept C90924648 @default.
• W4298088251 hasConceptScore W4298088251C119060515 @default.
• W4298088251 hasConceptScore W4298088251C126322002 @default.
• W4298088251 hasConceptScore W4298088251C141071460 @default.
• W4298088251 hasConceptScore W4298088251C143998085 @default.
• W4298088251 hasConceptScore W4298088251C159110652 @default.
• W4298088251 hasConceptScore W4298088251C207103383 @default.
• W4298088251 hasConceptScore W4298088251C2776909242 @default.
• W4298088251 hasConceptScore W4298088251C2778019345 @default.
• W4298088251 hasConceptScore W4298088251C2780140570 @default.
• W4298088251 hasConceptScore W4298088251C44249647 @default.
• W4298088251 hasConceptScore W4298088251C71924100 @default.
• W4298088251 hasConceptScore W4298088251C90924648 @default.
• W4298088251 hasFunder F4320321001 @default.

• next